Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020September 16, 2020 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

Prana receives $6.8 million R&D Tax Incentive Refund

June 19, 2015

PLoS ONE Journal Publishes Mechanistic Model of Alzheimer’s Disease Endorsing Prana’s PBT2

July 17, 2013

Prana Biotechnology Investor Presentation

June 27, 2018

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

Alterity presents at Finance News Network investor event
AGM 2020 Presentation
Chairman’s Address to Shareholders 2020 Annual General Meeting
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065